• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Revascularization  • Thrombolysis  • Oncology  • Oncology, Other  • Cardiovascular System  • Quality of Care  • Patient Safety/ Medical Error  • Cardiovascular/ Cardiothoracic Surgery  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

James S. Floyd, MD; Victor L. Serebruany, MD, PhD

Arch Intern Med. 2010;170(12):1078-1080.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

On July 10, 2009, the US Food and Drug Administration (FDA) approved prasugrel for use in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention based on the results of the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 (TRITON–TIMI 38), a multicenter randomized clinical trial of 13 608 patients that showed a 19% relative risk reduction in the composite end point of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death with prasugrel compared with clopidogrel.^1-2 Like other thienopyridines, prasugrel irreversibly inhibits platelet activation and aggregation through a P2Y12-receptor dependent mechanism. However, based on conventional aggregation studies, the approved daily dose of prasugrel (10 mg) appears to be 2.5 to 2.7 times more potent than the standard 75-mg daily dose of clopidogrel, and a 50% increase in life-threatening hemorrhage and a 4-fold . . . [Full Text of this Article]

AUTHOR INFORMATION
Author Affiliations: Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle (Dr Floyd); and HeartDrug Research Laboratories, Johns Hopkins University, Towson, Maryland (Dr Serebruany).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Antiplatelet Drugs: What Comes Next?
Kei et al.
CLIN APPL THROMB HEMOST 2011;17:9-26.
ABSTRACT  

Platelet Inhibition and Cancer Promotion
Goldstein et al.
Arch Intern Med 2010;170:1943-1944.
FULL TEXT  

Prasugrel and Cancer
Cattaneo
Arch Intern Med 2010;170:1944-1944.
FULL TEXT  

Letter by Serebruany Regarding Article, "Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38"
Serebruany
Circulation 2010;122:e436-e436.
FULL TEXT  

Prasugrel and Cancer: An Uncertain Association or a Credible Risk That Meaningfully Alters the Benefit-Risk Balance
Kaul and Diamond
Arch Intern Med 2010;170:1010-1012.
FULL TEXT